- Home
- GILD
GILD
Gilead Sciences Inc.
as 06-18-2025 4:00pm EST
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 129.9B | IPO Year: | 1992 |
| Target Price: | $110.17 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 4.73 | EPS Growth: | 1118.07 |
| 52 Week Low/High: | $62.69 - $119.96 | Next Earning Date: | 08-07-2025 |
| Revenue: | $28,735,000,000 | Revenue Growth: | 4.68% |
| Revenue Growth (this year): | 1.55% | Revenue Growth (next year): | 3.69% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | GILD | Chairman & CEO | May 30 '25 | Sell | $110.54 | 10,000 | $1,104,192.61 | 623,852 | |
| Mercier Johanna | GILD | Chief Commercial Officer | May 22 '25 | Sell | $107.52 | 28,000 | $3,010,563.60 | 121,152 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | May 15 '25 | Sell | $99.82 | 2,500 | $249,550.00 | 165,674 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Apr 15 '25 | Sell | $106.40 | 2,500 | $266,000.00 | 165,674 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Insider Monkey
3 days ago
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern
Insider Monkey
5 days ago
RBC Capital Lifts Gilead Sciences (GILD) PT to $95 On Insights From a 2022 Patient Survey
Zacks
8 days ago
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
MT Newswires
9 days ago
Gilead Sciences' Lenacapavir Provides 'Solid' Switching Opportunities for Current PrEP Users, RBC Says
TipRanks
9 days ago
Citi sees Gilead clinical holds as only ‘minor setback’
TipRanks
9 days ago
Gilead weekly oral hold should not affect lenacapavir PDUFA, says RBC Capital
TipRanks
9 days ago
FDA placed clinical hold on Gilead HIV treatment trials of GS-1720
Zacks
9 days ago
FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.